Patents by Inventor Kay-Gunnar Stubenrauch

Kay-Gunnar Stubenrauch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200309786
    Abstract: The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.
    Type: Application
    Filed: February 6, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Janis BROCKHAUS, Astrid REISER, Mirko RITTER, Kay-Gunnar STUBENRAUCH, Rudolf VOGEL, Markus ZADAK
  • Patent number: 10761097
    Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 1, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 10761091
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 1, 2020
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Patent number: 10683345
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 16, 2020
    Assignee: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Publication number: 20200093861
    Abstract: The present invention generally relates to antigen binding receptors in new formats capable of specific binding to a tumor associated antigen. More precisely, the present invention relates to an antigen binding receptor which efficiently and specifically binds to/interacts with an antigen on the surface of a tumor cell, and to a T cell transfected/transduced with the antigen binding receptor. Furthermore, the invention relates to nucleic acid molecules and vectors encoding antigen binding receptors of the present invention. The invention also provides the production and use of T cells in a method for the treatment of particular diseases as well as pharmaceutical compositions/medicaments comprising antigen binding receptors and/or T cells of the present invention.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Ekkehard MOESSNER, Diana DAROWSKI, Kay-Gunnar STUBENRAUCH
  • Publication number: 20200093860
    Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar STUBENRAUCH, Ekkehard MOESSNER, Christian KLEIN, Diana DAROWSKI
  • Patent number: 10502746
    Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1 or more and an antibody binding to rat IgG2c with an avidity of 9.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Publication number: 20190170765
    Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.
    Type: Application
    Filed: August 21, 2018
    Publication date: June 6, 2019
    Inventors: Wolfgang HOESEL, Kay-Gunnar STUBENRAUCH, Rudolf VOGEL
  • Publication number: 20190119383
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: September 21, 2018
    Publication date: April 25, 2019
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Publication number: 20190094216
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Patent number: 10168326
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 1, 2019
    Assignee: F. HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Publication number: 20180364251
    Abstract: Herein is reported a method for the determination of the amount of a bivalent antibody in a serum or plasma sample obtained from a non-human experimental animal, whereby the antibody comprises one or more mutations in the Fc-region compared to the corresponding wild-type Fc-region that has a sequence of SEQ ID NO: 01, 02, or 03, wherein the method comprises the following steps a) immobilizing a non-antibody polypeptide to which more than one copy of the antigen of the antibody is covalently conjugated on a solid surface, b) incubating the immobilized antigen with the sample to form an immobilized antigen-antibody complex, c) incubating the immobilized antigen-antibody complex with the antigen conjugated to a detectable label to form an immobilized ternary complex, and d) determining the amount of the antibody by determining the amount of the detectable label in the immobilized ternary complex.
    Type: Application
    Filed: May 24, 2018
    Publication date: December 20, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Kay-Gunnar Stubenrauch
  • Publication number: 20180346602
    Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.
    Type: Application
    Filed: April 25, 2018
    Publication date: December 6, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
  • Publication number: 20180328942
    Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
    Type: Application
    Filed: March 16, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar STUBENRAUCH, Uwe WESSELS
  • Patent number: 9957331
    Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: May 1, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Essig, Stefan Klostermann, Frank Kowalewsky, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Patent number: 9945869
    Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 17, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 9933433
    Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 3, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Essig, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Publication number: 20170370941
    Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1or more and an antibody binding to rat IgG2c with an avidity of 9.
    Type: Application
    Filed: September 18, 2015
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Publication number: 20170343560
    Abstract: Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 30, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo Umana, Uwe Wessels, Kay-Gunnar Stubenrauch
  • Patent number: 9766251
    Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 19, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Essig, Stefan Klostermann, Frank Kowalewsky, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels